Importantly, as a tumor suppressor, FBP1 is generally depleted in ccRCC (11); thus, upregulating the expression of FBP1 is a potential therapeutic strategy for cancer. This evidence concerns the gene FBP1 and nonpapillary renal cell carcinoma.